ABSTRACT
INTRODUCTION S
ECRETORY IgA (S-IgA), the major immunoglobulin isotype present at mucosal surfaces, is an important factor in local immunity (20, 35) . S-IgA is derived from the J chain-containing polymeric IgA (pIgA) produced by plasma cells, which are found in large numbers in secretory glands and in the lamina propria of mucosal tissues (11, 20) . Polymeric IgA, present in the interstitial fluid bathing the basolateral surfaces of the mucosal epithelial cells, is transported through these cells by the transmembrane polymeric immunoglobulin receptor (pIgR), which binds to the pIgA molecule and carries it from the basolateral to the apical cell surface (12) . There the receptor is cleaved, releasing the S-IgA molecule containing a large portion of the bound pIgR, known as secretory component (SC), into the mucosal secretions (4, 20) .
The majority of IgA-positive plasma cells in mucosal tissues migrate there from IgA-inductive sites such as the gutassociated lymphoid tissue (GALT) and the bronchus-associated lymphoid tissue (BALT) (20) . Stimulation of these IgA-inductive sites by antigens results in dissemination of specific IgA-producing cells to effector sites throughout the mucosal tissues (9, 19, 25, 44) , leading to the concept of a common mucosal immune system (20) .
The female reproductive tract is an integral part of this common mucosal system (5, 6, 19) . Immunization of the respiratory tract with liposomes supplemented with influenza viral hemagglutinin, for example, stimulates an IgA response in the murine uterus (9, 44) . There are numerous studies correlating S-IgA production in the female reproductive tract with immunity (1,4,7,10,14-17, 21-23,25,27,36,43) ; however, a role for S-IgA in protection of the female reproductive tract against viral infection has not been directly demonstrated.
In mice, plasma-derived pIgA can protect the upper respiratory tract from viral infection, as the passive transfer of nasal immunity to influenza virus has been accomplished via the intravenous injection of pIgA anti-influenza virus monoclonal antibody (mAb) (29, 30, 32, 33) . Influenza virus replicates in fetal urogenital tissue from ferrets (40) , guinea pigs (39) , and humans (34) , as well as in organ cultures of human and simian urogenital tissues and in human endometrial cell lines (2, 34) . In the work described in this paper, we investigated in a murine model whether the uterus might support the growth of influenza virus and whether uterine immunity might then be evaluated by the passive transfer of pIgA anti-influenza virus mAb.
MATERIALS AND METHODS

Animals
Four-to 6-week-old female BALB/c mice for experimental protocols or retired breeder female mice for ascites production were obtained from Charles River Breeding Laboratories (Wilmington, MA) and maintained in an Association for the Assessment and Accreditation of Laboratory Animal Care-accredited animal facility. Food and water were supplied ad libitum. Experimental protocols were approved by an institutional animal care and use committee.
Monoclonal IgA
Hybridoma H37-66-1, producing monoclonal pIgA specific for the Sb epitope of the hemagglutinin of PR8 (A/PR8/34) H1N1 influenza virus, was the generous gift of W. Gerhard (Wistar Institute, Philadelphia, PA) and was generated as previously described (37) . Hybridoma Z-F11-15, producing a pIgA not reacting with influenza virus, was the gift of Z. Moldoveanu (University of Alabama at Birmingham, Birmingham, AL). The hybridomas were propagated as ascitic tumors in retired breeder mice. Ascitic fluid was harvested, pooled, and stored at Ϫ70°C. Pooled H37-66-1 ascitic fluid contained pIgA at 8.6 mg/mL as determined by radial immunodiffusion assay (ICN ImmunoBiologicals, Lisle, IL); pooled Z-F11-15 contained 5.7 mg/mL pIgA mAb. On the basis of the amount of background IgA present in several IgG ascites pools (radial immunodiffusion assay determination), RENEGAR ET AL.
H37-66-1 pools contained less than 3% nonspecific IgA antibody. Both sucrose gradient sedimentation (30) and ACA column chromatography (31) showed H37-66-1 pools to be composed of greater than 75% polymeric antibody forms. Sedimentation analysis of H-37-66-1 pIgA mAb collected from the nasotracheal lavages and bile of intravenously injected mice showed that the mAb retained its polymeric form on transport (30) . Furthermore, H-37-66-1 injected intravenously into a Lewis rat and collected by bile duct cannulation acquired secretory component as it was removed from the circulation (31), indicating that it was a J chain-containing polymeric IgA and not simply an aggregate of monomeric IgA molecules.
Virus
A/PR8-Mt. Sinai (H1N1) influenza virus was the gift of W. Gerhard. To generate a pool, virus was grown in eggs, pooled, filtered through a 0.45-m pore size filter, aliquoted, and stored at Ϫ70°C. Viral growth was assayed in Madin-Darby canine kidney (MDCK) cells as described below and viral titers were calculated by the method of Reed and Muench (28) . The log 10 TCID 50 (50% infectious dose in tissue culture) of the virus pool was 5.6.
Uterine infection protocol
Eight-to 10-week-old female BALB/c mice were anesthetized by intramuscular injection of a mixture of 1 mg of ketamine plus 1 mg of xylazine. A 2.5-cm incision was made parallel and dorsal to the lumbar spine, the ovaries were exteriorized, and each ovarian bursa was injected with 2 ϫ 10 2.5 TCID 50 of PR8 influenza virus (volume, 20 L), using a 30-gauge needle. The surgical procedure was performed under a dissecting microscope. The incision was closed with 3-0 wire sutures to discourage gnawing of the healing wound. At various times postinfection, mice were killed (by intravenous injection of 30 mg of xylazine) and the uterus was removed for assay. The uterus and uterine horns were flushed with 600 L of cold (4°C) sterile phosphate-buffered saline (PBS) and the wash fluid was saved for viral assay. The washed uterus was then ground in 600 L of cold sterile PBS and centrifuged at 1000 rpm to remove debris, and the supernatants were assayed for virus. To preserve viral viability, samples (washes and ground uterus supernatants) were not frozen but were kept on ice and assayed as described below within 1 h.
Viral assay
A modification of the viral assay originally developed by Wyde et al. (47) 
Histology
Uteri were removed from killed normal mice or from mice infected intrabursally 96 h previously with influenza virus. One horn of each uterus was processed for light microscopy and one for scanning electron microscopy. For light microscopy, samples were fixed in 10% neutral buffered formalin, embedded in paraffin, cut into 2-m sections, and stained with hematoxylin and eosin. For electron microscopy, samples were fixed in glutaraldehyde-cacodylate buffer (2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer) and stored at 4°C until processed. For processing, samples were postfixed with 1% osmium tetroxide, dehydrated with successive transfers to 70%, 90%, and absolute ethanol, and dried in a desiccator after treatment with hexamethyldisilane. The samples were then mounted and coated to a thickness of 80 nm with gold-palladium.
Protection protocol
Female BALB/c mice were injected intravenously via the tail vein with 200 L of H66-37-1 or Z-F11-15 ascites mixed with 200 L of saline. The ascites was centrifuged before injection to preclude embolus formation. Four hours later, the mice were anesthetized and infected as previously described. In some cases, mice were infected first and injected with H66-37-1, 30 min later. Mice were killed at various times postinfection and their uteri were assayed for viral growth as described.
Antibody transport protocol
Twelve 8-to 10-week-old female BALB/c mice were injected intravenously via the tail vein with 200 L of pIgA anti-influenza mAb-containing ascitic fluid that had been centrifuged to preclude embolus formation and
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mixed with 200 L of saline (dose of 1700 g of pIgA per mouse). At 2, 4, and 8 h postinjection four mice were injected intravenously with 30 mg of xylazine. The chest was opened and the mouse was perfused with PBS to minimize contamination of uterine lavages with blood contained within the vascular system. An 18-gauge needle attached to a 60-mL syringe containing 50 mL of PBS was placed in the left ventricle of the heart and clamped in place with a hemostat. An incision was made in the right ventricle to allow drainage and the circulatory system was perfused with the PBS. Perfusion was monitored by observation of the liver, which became clay-colored as blood was flushed from the system. The intact uterus was then clamped proximal to the cervix with a curved hemostat and excised with the cut immediately proximal to the cervix, its exterior rinsed with PBS to remove any trace of blood, and the interior lavaged with 600 L of PBS, which was flushed once through each horn and collected in a microcentrifuge tube as it drained from the distal end of the uterus.
Antibody titer determination
Uterine wash pIgA anti-influenza virus mAb titers were determined by a modification of the enzyme-linked immunosorbent assay (ELISA) previously described (32) . PR8 influenza vaccine (the gift of F. Brandon, Parke, Davis, and Co., Rochester, MI) was dried onto 96-well flat-bottom enzyme immunoassay (EIA) microtiter trays (EIA II Plus microtitration plates; MP Biomedicals, Solon, OH). Unreacted sites were blocked overnight at 4°C with PBS-Tween containing 1% bovine serum albumin (BSA) for ELISA diluent applications (Sigma) and 1% normal rabbit serum (NRS). All antibodies were diluted in PBS-Tween containing 1% bovine serum albumin (BSA) and 1% NRS and PBS-Tween was used for all plate washes. After overnight blocking, the plates were washed, uterine wash samples were added in triplicate, and the trays were incubated overnight at 4°C. The plates were washed, and the second and third antibodies were added and incubated for 1.5 h at room temperature. Affinity-purified goat anti-mouse IgA was the second antibody, and the final antibody was rabbit anti-goat IgG coupled to alkaline phosphatase (NRS and both antibodies were obtained from Sigma). Reaction with the substrate p-nitrophenyl phosphate (Sigma) produced a yellow color that was read at 405 nm as an end-point ELISA on a Spectromax 190 ELISA reader (Molecular Devices, Sunnyvale, CA). Titers were calculated from sample dilutions relative to a dilution of the standard pIgA mAb. The titer is defined as the ratio of the dilution of sample required to give a specific ELISA optical density (OD) to the dilution of the standard required to give the same OD (parallel line method), expressed as a percentage. For example, a sample with a titer of 1 ϫ 10 Ϫ3 contains 0.001% as much antibody as the ascites standard. The ascites pool used as the standard contained an 8.6-mg/mL concentration of pIgA anti-influenza virus mAb. Standard wells containing known concentrations of mAb from this pool were included on each ELISA plate so that the concentration of transported mAb in the uterine lavages could be readily determined.
Because binding of antibody to the influenza vaccinecoated plates requires antibody specificity, this ELISA detects only the intravenously injected influenza virusspecific mAb.
Statistics
All data are expressed as means Ϯ SD. Nonparametric (Mann-Whitney) and parametric (analysis of variance [ANOVA] and Fisher's protected least significant difference [PLSD]) analyses were carried out on a Macintosh Performa using StatView 4.2 (SAS Institute, Cary, NC) software.
Graphics
Figures were generated with CA-Cricket Graph III software (CA, Islandia, NY) on an Apple iBook (Apple Computer, Cupertino, CA). Photomicrographs were also processed on the Apple iBook, using Adobe Photoshop 7.0 software.
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RESULTS
Influenza virus grows in the murine uterus
Growth of PR8 influenza virus in the murine uterus is shown in Fig. 1 . Similar viral titers (10 4 to 10 5 TCID 50 ) were reached in both uterine washes and ground uterus. The highest virus titers occurred 3 to 5 d after infection. This finding mimicks the growth pattern seen in the nose, trachea, and lungs when the influenza virus is inoculated into the noses of awake nonimmune mice (24) .
Histologic studies were performed 96 h after viral infection, at the time of peak viral titer. By light microscopy, the most notable pathology associated with viral infection was the loss of cilia from the epithelial cells 
FIG. 2.
Light microscopy of the murine oviduct. Mice were infected via injection of the ovarian bursa with 2 ϫ 10 2.5 TCID 50 of PR8 influenza virus. Ninety-six hours postinfection, infected and noninfected control animals were killed and the uterus was removed for light and scanning electron microscopy analysis. Normal murine oviduct is lined by ciliated cells with tapered tips [arrow in (A)]. After influenza infection, the cilia were lost and the epithelial cells lining the interior of the ovarian bursa were necrotic with condensed, pycnotic nuclei and indistinct cellular outlines. Areas of desquamation [arrows in (B)] were evident. Original magnification: ϫ400.
lining the oviduct (Fig. 2B) . Neither the uterus nor the oviduct displayed the extensive desquamation seen in the tracheas of influenza virus-infected mice (13, 48) ; however, the 96-h time frame may have been too short for the full pathologic effects of the infection to develop, The ciliated columnar epithelial cells lining the oviduct of infected mice appeared necrotic, with pycnotic nuclei and indistinct cellular outlines. Areas of limited desquamation were present and cells within the submucosa were farther apart than those in the noninfected tissue, suggesting the presence of interstitial edema. The uterine epithelium showed similar pathology, with pycnotic nuclei, indistinct cellular architecture, and minimal desquamation. Scanning electron microscopy ( Fig. 3) confirmed the clipping of the cilia of the oviduct. In normal mice, the oviduct was characterized by both short microvilli and longer cilia with slightly rounded tapered tips (Fig.  3A) . In infected mice, both the microvilli and the cilia were severely blunted. The cilia were shortened and deformed ( Fig. 3B ) and, in some cases, adhered to each other (Fig. 3C) .
Influenza virus-specific pIgA is transported into the uterus
To demonstrate that intravenously administered pIgA can be transported into the uterus, a single intravenous injection of 1700 g of pIgA anti-influenza virus mAb (the dose shown to saturate the murine transport system [30, 32] ) was administered to 12 mice. Four mice were killed 2, 4, or 8 h postinjection and uterine lavages were performed to harvest the transported antibody. Passively administered pIgA antibody was, as previously reported in the rat, transported into murine uterine secretions (46) . The pattern (Fig. 4A and B 
Influenza virus-specific pIgA protects the uterus from infection
H66-37-1 is a pIgA mAb directed toward the H1 hemagglutinin of the A/PR8 influenza virus. We have shown that it can be transported into the bile of Lewis rats, acquiring SC in the process (31) , and into murine nasal secretions, presumably also by the pIgR, and that the transported antibody retains its polymeric form and can prevent infection of the murine nose by influenza virus (30, 32) . To determine whether this antibody can also protect the murine uterus from viral infection, female BALB/c mice were injected intravenously with 1700 g of pIgA anti-influenza virus mAb or with saline 4 h before injection of virus into the ovarian bursa. Viral growth in passively immunized animals was determined 1, 2, and 3 d after viral infection (Table 1) . On days 1 and 2 all the mice injected with influenza virusspecific pIgA mAb were protected from viral infection, regardless of whether uterine washes or ground uteri were assayed. On day 3, 9 of 12 uterine washes and 7 of 8 ground uteri from H66-injected mice showed no viral infection (Table 1 ). Those influenza virus-specific pIgA mAb-injected mice that shed virus (Table 2 ) did so at a reduced titer relative to saline-injected mice whether in uterine washes (p Ͻ 0.001) or ground uterus (p Ͻ 0.05). Injection of Z-F11-15, a pIgA of unrelated specificity, did not protect against influenza virus infection.
Under the standard protocol, mice were injected first with antibody, and then challenged with virus. To rule out the possibility that blood with a high titer of influenza virus-specific pIgA leaking into the ovarian bursa via the 617   FIG. 3 . Scanning electron photomicrographs of the murine oviduct. Mice were infected via injection of the ovarian bursa with 2 ϫ 10 2.5 TCID 50 of PR8 influenza virus. Ninety-six hours postinfection, infected and noninfected control animals were killed and the uterus was removed for light and scanning electron microscopy analysis. Epithelial cells lining the normal murine oviduct (A) bear both long cilia and shorter microvilli. These cilia, like those of the respiratory tract, have tapered tips. In the influenza virus-infected oviduct, microvilli and cilia are short and blunted (B) and, in some cases, form clumps (C). Original magnification: ϫ10,000. Scale bars: 1 m. small puncture at the inoculation site was neutralizing the virus before initial cellular infection, mice were first infected with influenza virus, and then injected with antibody 30 min later, allowing the initial stage of viral infection to occur before antibody injection. Mice treated in this manner were still protected ( Table 2 ), suggesting that protection was due to antibody transported into the uterus, preventing further rounds of viral replication, and not to antibody-containing blood leaking into the ovarian bursa at the time of viral inoculation.
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DISCUSSION
Passive immunization studies of the murine respiratory and gastrointestinal tracts have shown that S-IgA alone is able to mediate local immunity against viruses (18, 32, 41, 42) and bacteria (8, 45) . The genitourinary tract is an important port of entry for pathogenic viruses and microorganisms. Involvement of S-IgA in uterine or cervicovaginal immunity has been implied by a number of studies correlating antibody levels with protection and/or recovery from infection (1,7,14,17,21-23,25,27,29,36,  43 ) and by two studies in which the continuous secretion of a high level of pIgA anti-Chlamydia mAb from a "backpack" tumor was able to slow the progress of chlamydial infection into the uterus after vaginal challenge in the mouse (8,26) ; however, there are no studies directly demonstrating the role of S-IgA in antiviral immunity in the female reproductive tract, possibly because of the complexity of the immune response to two of the major pathogens of interest, that is, the human immunodeficiency virus and herpes simplex virus type 2 viruses, and the difficulty in propagating these pathogens in the murine model. The demonstration of this immunity requires, first, a model for the consistent infection of the uterus and, second, an agent-specific pIgA capable of neutralizing the growth of the infective agent and of being transported to its potential site of action in vivo by the pIgR. Herein, we have demonstrated that the influenza virus model meets these requirements.
Although influenza virus is not a normal pathogen of the reproductive tract, the influenza viral infection model is one of the best characterized as far as antibody selective transport, isotype involvement, viral neutralization, and in vivo protection from viral infection are concerned. In addition, mice are easily infected with the mouseadapted PR8 influenza virus, the virus is easy to propagate and assay in vitro, its cellular receptors are well known, and it is safe to handle under general laboratory conditions Sweet et al. (40) showed that influenza virus grew in the oviduct of fetal ferrets. Additional studies with guinea pigs (39) and human fetal tissue (34) further demonstrated the growth of influenza virus in genitourinary tissues. We found that PR8 influenza virus, when injected into the ovarian bursa, was also capable of growing in the mature murine uterus. Infection was consistent and reproducible: virus could be detected in uterine secretions (uterine washes) or in uterine tissue in comparable amounts (Fig. 1) . Pathologic changes associated with viral infection were most severe in the ciliated cells of the oviducts (Figs. 2 and 3) , which underwent necrosis, losing their cilia in the process. Areas of desquamation were noted, as well as interstitial edema within the oviduct. The uterine epithelium showed similar, although not as severe, pathology. The viral pathology was not dissimilar to that seen in influenza viral infection of the murine respiratory tract, where the ciliated cells of the trachea undergo complete desquamation (13, 48) ; while the ciliated cells of the nose show blunting of the ciliary tips (33) .
Renegar and Small (32) showed that the anti-influenza virus pIgA mAb used in this study could be selectively transported into nasal secretions relative to monomeric immunoglobulin, that the time of peak transport was 4 h after injection, and that transported antibody was able to protect the nose against influenza viral infection. In this paper, we show that intravenously injected pIgA antiinfluenza virus mAb is also transported into uterine secretions and that peak transport, like that seen in the respiratory tract, occurs 4 h postinjection. The pIgA antiinfluenza virus mAb pool contained approximately 25%
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monomeric IgA, and therefore we cannot exclude the possibility that monomeric influenza-specific IgA mAb contributed to the observed uterine protection; however, because the polymeric form of pIgA comprised at least 75% of the pIgA pool used for injection and because any monomeric IgA included in the mAb dose would have been diluted in the normal intravascular monomeric immunoglobulin pool, we believe that protection in our model was due to S-IgA transported into the uterus by the pIgR. Sullivan and Wira (38) reported that uterine tissues were saturated with pIgA antibody by 2 to 4 h postinjection and that pIgR-mediated transport was seen by 4 h postinjection in estrogen-treated ovariectomized female rats. This is consistent with the 4-h postinjection IgA peak we observed. We have shown (30, 32) reaching the secretions remains relatively constant with increasing time postinjection, whereas the percent injected dose of pIgA peaks and then drops as hepatobiliary pIgR rapidly removes polymeric immunoglobulins from the circulation. In our uterine transport model ( Fig.  4A and B) , both the uterine anti-influenza virus mAb titer and the percent injected dose peaked 4 h postinjection. After this peak, both transport parameters fell to the 2-h level. This pattern is consistent with transport of pIgA into the uterus by the pIgR. Furthermore, selective transport into the murine uterus of pIgA relative to monomeric immunoglobulin has been shown to occur (selective transport index 4 h after antibody injection, 6.2 Ϯ 5.2; K.B. Renegar, unpublished data), indicating that pIgRmediated uterine transport of pIgA takes place. Hence, we believe that S-IgA mediated the uterine immunity in our model. We investigated uterine immunity using the same virus-antibody system previously used to study nasal immunity. As with protection of the respiratory tract, a single dose of anti-influenza virus pIgA mAb administered 4 h before viral challenge was able to protect the murine oviducts and uterus from influenza virus infection (Tables 1 and 2). Protection required specific antibody and occurred regardless of the order in which antibody and virus were administered. Because monomeric immunoglobulins readily enter uterine secretions, it is likely that not only pIgR-transported pIgA but also plasma influenza virus-specific IgG mAb can confer protection on the uterus. Further studies are required to delineate more completely the roles of IgA and IgG in uterine immunity.
In conclusion, we have shown that influenza virus will grow in the murine uterus, providing a model for the study of uterine immunity. Intravenously injected influenza virus-specific pIgA mAb was transported into the uterus and protected the uterus against viral infection. This is the first direct demonstration of the prevention of uterine viral infection by pIgA and we believe that it is also the first direct demonstration of the mediation of antiviral immunity in the uterus by S-IgA. This model should be useful in delineating the relative roles of IgA and IgG in uterine immunity; moreover, it should prove a valuable tool in determining the effect of hormonal variation on antibody-mediated uterine immunity.
